A novel liquid chromatography‐fluorescence method for the determination of delafloxacin in human plasma

Hernandis, Verónica; Escudero, Elisa; Marı́n, Pedro

doi:10.1002/jssc.202100768

Cited by 8 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using the ratio C max /MIC (C max : maximal concentration) enables the assessment of the risk of resistance emergence to FQs [ 15 ]. To note, several chromatography methods are already available to monitor DLX plasmatic concentrations [ 34 , 35 ]. The studies of pharmacokinetics and pharmacodynamics (PK/PD) parameters of DLX have shown that the total exposure following a single 300 mg intravenous (IV) dose and a single 450 mg oral (PO, per os) dose is equivalent, allowing change in administration ways.…”

Section: Pharmacokinetics and Pharmacodynamicsmentioning

confidence: 99%

Updated Review on Clinically-Relevant Properties of Delafloxacin

Turban¹,

Guérin

Dinh

et al. 2023

Antibiotics

View full text Add to dashboard Cite

The extensive use of fluoroquinolones has been consequently accompanied by the emergence of bacterial resistance, which triggers the necessity to discover new compounds. Delafloxacin is a brand-new anionic non-zwitterionic fluoroquinolone with some structural particularities that give it attractive proprieties: high activity under acidic conditions, greater in vitro activity against Gram-positive bacteria—even those showing resistance to currently-used fluoroquinolones—and nearly equivalent affinity for both type-II topoisomerases (i.e., DNA gyrase and topoisomerase IV). During phases II and III clinical trials, delafloxacin showed non-inferiority compared to standard-of-care therapy in the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, which resulted in its approval in 2017 by the Food and Drug Administration for indications. Thanks to its overall good tolerance, its broad-spectrum in vitro activity, and its ease of use, it could represent a promising molecule for the treatment of bacterial infections.

show abstract

Section: Pharmacokinetics and Pharmacodynamicsmentioning

confidence: 99%

Updated Review on Clinically-Relevant Properties of Delafloxacin

Turban¹,

Guérin

Dinh

et al. 2023

Antibiotics

View full text Add to dashboard Cite

show abstract

“…6.1.5. Potential Role of TDM Liquid chromatography methods have been developed for PK analyses of delafloxacin [188,189,192]. However, no TDM studies have been published and no PK/PD safety/efficacy thresholds have been identified yet.…”

Section: Pk/pd Characteristicsmentioning

confidence: 99%

New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians

Carcione,

Intra,

Andriani

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Antibiotic resistance is a public health problem with increasingly alarming data being reported. Gram-positive bacteria are among the protagonists of severe nosocomial and community infections. The objective of this review is to conduct an extensive examination of emerging treatments for Gram-positive infections including ceftobiprole, ceftaroline, dalbavancin, oritavancin, omadacycline, tedizolid, and delafloxacin. From a methodological standpoint, a comprehensive analysis on clinical trials, molecular structure, mechanism of action, microbiological targeting, clinical use, pharmacokinetic/pharmacodynamic features, and potential for therapeutic drug monitoring will be addressed. Each antibiotic paragraph is divided into specialized microbiological, clinical, and pharmacological sections, including detailed and appropriate tables. A better understanding of the latest promising advances in the field of therapeutic options could lead to the development of a better approach in managing antimicrobial therapy for multidrug-resistant Gram-positive pathogens, which increasingly needs to be better stratified and targeted.

show abstract

“…4 This is later associated by Cempra. 5 Veronica Hernandis et al, 6 measured plasma delafloxacin strengths by RP chromatography. Wavelength is 405m and 450nm.…”

Section: Introductionmentioning

confidence: 99%

Validation and Development of a Method for Identification and Stability Analysis of Delafloxacin Separation Using LC-MS/MS

Sarbudeen,

Abbaraju,

Padmalatha

et al. 2024

Orient. J. Chem

View full text Add to dashboard Cite

In order todevelop and validate the technique for delafloxacin authors are used the peak intense which is furthermore improved to this present investigation employing a variety of parameters, which includes column, alteration of eluent ratio, and rate of flow.For this development authors are usedWaters column with 2.1 mm x 100 mm, 5µm, C18. Mobile phase as 0.2% formic acid with pH of 2.6 and acetonitrile in the proportion of 30v/v:70v/v. The retention was 1.2 minutes and the rate of flow is identified as 0.12 µL/min. Forced degradation studies reveals that the peaksobtained are homogeneousand there are noco-elutingpeaks. The % RSD was found to be 3.5. Six LLOQ concentrations (10 ng/ml-1)of delafloxacin were evaluated in order to carry out the precision study.The results of calibration curve were 232.8, 0.9968, and 1273, respectivelyfor slope, coefficient of correlation (r2), and intercept.Mass spectrum development is done by the utilization of MRM ion mode (ES+) with mass transitions of m/z 441.10 > 379.10 (amu). On ionization,both parent and daughter ions were identified. 10–150 ng/mL is the calibration curve which reveals that linear by lower quantification limit of 10.00ng/ml. LOQ- 50.00ng/ml, MOQ-100.00ng/ml, HOQ -150.00ng/ml set to accuracy studies.In this present study, the research could be very helpful inlocating other potential DPs and process-related impurities that might be present indelafloxacin in very small amounts.

show abstract

A novel liquid chromatography‐fluorescence method for the determination of delafloxacin in human plasma

Cited by 8 publications

References 27 publications

Updated Review on Clinically-Relevant Properties of Delafloxacin

Updated Review on Clinically-Relevant Properties of Delafloxacin

New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians

Validation and Development of a Method for Identification and Stability Analysis of Delafloxacin Separation Using LC-MS/MS

Contact Info

Product

Resources

About